EXTON, Pa., March 23, 2018 /PRNewswire/ — AbbVie’s Humira and Janssen’s Remicade have been the dominant agents in the moderate-to-severe ulcerative colitis market for years. Recently, Takeda’s Entyvio has been gaining momentum, and survey results predict significant gains for Entyvio in…